Wieslaw M Kazmierski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5113553/publications.pdf

Version: 2024-02-01

60 papers	4,222 citations	201385 27 h-index	123241 61 g-index
62 all docs	62 docs citations	62 times ranked	3291 citing authors

#	Article	IF	Citations
1	A new type of synthetic peptide library for identifying ligand-binding activity. Nature, 1991, 354, 82-84.	13.7	1,871
2	The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor. Molecular Pharmacology, 2005, 67, 1268-1282.	1.0	283
3	Design and synthesis of conformationally constrained somatostatin analogs with high potency and specificity for .mu. opioid receptors. Journal of Medicinal Chemistry, 1986, 29, 2370-2375.	2.9	189
4	Design and synthesis of somatostatin analogs with topographical properties that lead to highly potent and specific .mu. opioid receptor antagonists with greatly reduced binding at somatostatin receptors. Journal of Medicinal Chemistry, 1988, 31, 2170-2177.	2.9	131
5	Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 2663-2676.	1.4	117
6	Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity. Journal of the American Chemical Society, 1991, 113, 2275-2283.	6.6	116
7	A new approach to receptor ligand design: synthesis and conformation of a new class of potent and highly selective Î¼ opioid antagonists utilizing tetrahydroisoouinoline carroxylic acid. Tetrahedron, 1988, 44, 697-710.	1.0	96
8	N-(2-Benzoylphenyl)-l-tyrosine PPARÎ³ Agonists. 2. Structureâ^'Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. Journal of Medicinal Chemistry, 1998, 41, 5037-5054.	2.9	93
9	The Relative Activity of â€œFunction Sparingâ€•HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property?. Molecular Pharmacology, 2009, 75, 490-501.	1.0	79
10	The chemical synthesis of large random peptide libraries and their use for the discovery of ligands for macromolecular acceptors. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 419-424.	1.0	76
11	Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5689-5692.	1.0	58
12	New Amino Acids for the Topographical Control of Peptide Conformation: Synthesis of All the Isomers of .alpha.,.beta.-Dimethylphenylalanine and .alpha.,.beta.-Dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid of High Optical Purity. Journal of Organic Chemistry, 1994, 59, 1789-1795.	1.7	53
13	DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 3552-3562.	2.9	52
14	Peptide, Peptidomimetic and Small-molecule Drug Discovery Targeting HIV-1 Host-cell Attachment and Entry through gp120, gp41, CCR5 and CXCR4+. Chemical Biology and Drug Design, 2006, 67, 13-26.	1.5	49
15	Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7317-7322.	1.0	45
16	Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3431-3433.	1.0	43
17	Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors*. International Journal of Peptide and Protein Research, 1990, 35, 566-573.	0.1	43
18	Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2048-2054.	1.0	43

#	Article	IF	Citations
19	Synthesis and evaluation of novel Î±-amino cyclic boronates as inhibitors of HCV NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3550-3556.	1.0	41
20	A solid-phase approach to analogues of the antibiotic mureidomycin. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2759-2763.	1.0	39
21	Total Synthesis and Semi-Synthetic Approaches to Analogues of Antibacterial Natural Product Althiomycin. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 561-565.	1.0	39
22	Novel Spiroketal Pyrrolidine GSK2336805 Potently Inhibits Key Hepatitis C Virus Genotype 1b Mutants: From Lead to Clinical Compound. Journal of Medicinal Chemistry, 2014, 57, 2058-2073.	2.9	39
23	Discovery of Bioavailable 4,4-Disubstituted Piperidines as Potent Ligands of the Chemokine Receptor 5 and Inhibitors of the Human Immunodeficiency Virus-1. Journal of Medicinal Chemistry, 2008, 51, 6538-6546.	2.9	37
24	Discovery of Novel Urea-Based Hepatitis C Protease Inhibitors with High Potency against Protease-Inhibitor-Resistant Mutants. Journal of Medicinal Chemistry, 2012, 55, 3021-3026.	2.9	37
25	Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1â€“P2 scaffold. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5685-5687.	1.0	36
26	Novel macrocyclic HCV NS3 protease inhibitors derived from Î±-amino cyclic boronates. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5695-5700.	1.0	34
27	Novel 4,4-Disubstituted Piperidine-Based Câ€“C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile. Journal of Medicinal Chemistry, 2011, 54, 3756-3767.	2.9	30
28	Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7493-7497.	1.0	28
29	Discovery of Next Generation Inhibitors of HIV Protease. Current Topics in Medicinal Chemistry, 2005, 5, 1589-1607.	1.0	27
30	Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of Î±,Î²-dimethyl-phenylalanine and Î±,Î²-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. Tetrahedron Letters, 1991, 32, 5769-5772.	0.7	25
31	Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A. Antimicrobial Agents and Chemotherapy, 2014, 58, 38-47.	1.4	25
32	Conformationally restricted analogs of oxytocin; stabilization of inhibitory conformation^{â€}. International Journal of Peptide and Protein Research, 1990, 36, 321-330.	0.1	23
33	Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via Oâ†'N acyloxy migration of P1 moiety. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2523-2526.	1.0	22
34	[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1610-1613.	1.0	21
35	New, potent P1/P2-morpholinone-based HIV-protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5226-5230.	1.0	20
36	Characterization of Apoâ€Form Selective Inhibition of Indoleamine 2,3â€Dioxygenase**. ChemBioChem, 2021, 22, 516-522.	1.3	20

#	Article	IF	Citations
37	Proton n.m.r. investigation of conformational influence of penicillamine residues on the disulfide ring system of opioid receptor selective Somatostatin derivatives. International Journal of Peptide and Protein Research, 1988, 31, 192-200.	0.1	18
38	Reduced peptide bond cyclic somatostatin based opioid octapeptides Synthesis, conformational properties and pharmacological characterization. International Journal of Peptide and Protein Research, 1992, 39, 401-414.	0.1	17
39	Conformation of two somatostatin analogues in aqueous solution. Study by NMR methods and circular dichroism. FEBS Journal, 1989, 185, 371-381.	0.2	16
40	Inhibitors of Human Immunodeficiency Virus Type 1 Derived from gp41 Transmembrane Protein:Â Structureâ^'Activity Studies. Journal of Medicinal Chemistry, 1996, 39, 2681-2689.	2.9	14
41	4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4988-4992.	1.0	14
42	Metal chelating amino acids in the design of peptides and proteins. Synthesis of NÎ±-Fmoc/But protected amino acids incorporating aminodiacetic acid moiety.. Tetrahedron Letters, 1993, 34, 4493-4496.	0.7	12
43	Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1394-1398.	1.0	12
44	Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations. Journal of General Virology, 2014, 95, 363-372.	1.3	12
45	Synthesis of the carbonic acid benzotriazol-1-yl-ester-(2-biotinylamino)-9h-fluoren-9-ylmethyl ester: A convenient transient-biotinylation reagent for use in affinity chromatography. Tetrahedron Letters, 1995, 36, 9097-9100.	0.7	11
46	Discovery of a novel series of cyclic urea as potent CCR5 antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6381-6385.	1.0	11
47	Biological and Structural Characterization of Rotamers of Câ€“C Chemokine Receptor Type 5 (CCR5) Inhibitor GSK214096. ACS Medicinal Chemistry Letters, 2014, 5, 1296-1299.	1.3	11
48	Synthesis of 4â€Substituted Piperidines via a Mild and Scalable Twoâ€Step Cu2Oâ€Mediated Decarboxylation of Cyanoesters. Synthetic Communications, 2006, 36, 279-284.	1.1	10
49	Discovery of N-benzyl-Nâ€²-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): Optimization of the amine portion. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7397-7400.	1.0	9
50	Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6470-6475.	1.0	9
51	Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1141-1145.	1.0	9
52	GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage. Journal of Medicinal Chemistry, 2020, 63, 4155-4170.	2.9	9
53	HCV Inhibition Mediated Through the Nonstructural Protein 5A (NS5A) Replication Complex. Annual Reports in Medicinal Chemistry, 2012, 47, 331-345.	0.5	8
54	A New Experimental Method to Determine the Mutual Orientation of Helices in Coiledâ€Coil Proteins: Structural Information about the Dimeric Interface of cJun, cFos, GCN4, and gp41. Chemistry - A European Journal, 1996, 2, 403-411.	1.7	6

#	Article	IF	Citations
55	Discovery of N-benzyl-Nâ€²-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): Modification of the acyl portion. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7401-7404.	1.0	6
56	Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7351-7356.	1.0	6
57	Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2993-2996.	1.0	6
58	Effects of a novel opioid peptide antagonist on rat bladder motility in vivo. Peptides, 1987, 8, 625-632.	1.2	4
59	Efficient synthesis of metal binding peptides incorporating aminodiacetic acid based ligands. International Journal of Peptide and Protein Research, 1995, 45, 241-247.	0.1	4
60	The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1649-1655.	1.3	2